Accuracy of Plasma Biomarkers for Detecting Amyloid Beta Deposits in Participants With Alzheimer’s Disease in ASCENT-2 Clinical Trial of PRX012 (P10-3.012)
This analysis retrospectively evaluated the ability of plasma biomarkers to identify Alzheimer’s disease (AD) clinical trial participants with positive amyloid beta (Aβ)-positron emission tomography (PET) results and explored plasma biomarker utility for prescreening in AD clinical trials.
Authors
- Ann Johnson
- Kevin Dougherty
- Brian Campbell (ORCID: https://orcid.org/0000-0001-9387-4580)
- C. P. Fitzgerald (ORCID: https://orcid.org/0000-0002-3542-3869)
- Ryan E. Tooker
- Wagner Zago (ORCID: https://orcid.org/0009-0002-5244-5098)
- Karen J. Quadrini (ORCID: https://orcid.org/0009-0001-3113-5800)
- Chad J. Swanson
- Jiri Aubrecht (ORCID: https://orcid.org/0000-0003-4304-2430)
- Mary Quiceno
Institutions
- Prothena (United States) (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210621
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00